QIAGEN to develop QuantiFERON-TB Access as a new test for low-resource, high-burden regions in global fight against TB

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to develop a proprietary new version of a QuantiFERON®-based tuberculosis (TB) test dedicated and tailored to the needs of low-resource regions with a high disease burden of TB. The new testing solution, QuantiFERON®-TB Access (QFT® Access), is designed to pair ultrasensitive digital detection of Read more about QIAGEN to develop QuantiFERON-TB Access as a new test for low-resource, high-burden regions in global fight against TB[…]

EnWave Receives Purchase Order for Third 120kW REVTM Machine from Milne Fruit Products

EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company" – http://www.commodity-tv.net/c/search_adv/?v=297852) announced today that it has signed an Equipment Purchase Agreement (the “EPA”) with Milne Fruit Products d.b.a. Milne MicroDried Inc. (“Milne”)  to provide Milne with its third 120kW Radiant Energy Vacuum (“REV™”) machine for the production of an extensive portfolio of dried vegetable and Read more about EnWave Receives Purchase Order for Third 120kW REVTM Machine from Milne Fruit Products[…]

EnWave Signs Research and Development License Agreement with Cornell University, Receives Purchase Order for Small-Scale REVTM Machine for Cornell’s Center of Excellence

EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company" – http://www.commodity-tv.net/c/search_adv/?v=298005) announced today that it has signed a Research and Development License Agreement (the "Agreement") with the College of Agriculture and Life Sciences at Cornell University (CALS). CALS has also committed to purchasing a 10kW Radiant Energy Vacuum (“REV™”) dehydration machine to be used at Read more about EnWave Signs Research and Development License Agreement with Cornell University, Receives Purchase Order for Small-Scale REVTM Machine for Cornell’s Center of Excellence[…]